Innovent Biologics May See Stronger Commercial Outlook -- Market Talk

Dow Jones

07/08

0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

July 08, 2025 00:56 ET (04:56 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549959430"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549959430\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549959430?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 12:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549959430","market":"us","top_or_hot":-1,"title":"Innovent Biologics May See Stronger Commercial Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics May See Stronger Commercial Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics May See Stronger Commercial Outlook -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-08 12:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSBA.UK","symbol_name":"滙豐控股有限公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2549959430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549959430","pubTimestamp":1751950560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSBA.UK":"汇丰控股有限公司","BK1161":"生物科技","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK1610":"ETF&股票定投概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1601":"香港本地股","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","HSHD.SI":"HSBC HK SDR 5to1","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","BK1583":"高瓴概念","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK1231":"综合性银行","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK4588":"碎股","03143":"华夏香港银行股","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4521":"英国银行股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","HSBC":"汇丰","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","BK1572":"香港银行股","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","BK1589":"北水核心资产","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","01801":"信达生物","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","00005":"汇丰控股","BK4585":"ETF&股票定投概念","BK4207":"综合性银行"},"translate_title":"信达生物可能会看到更强劲的商业前景——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.9,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.6,"HSHD.SI":0.6},"content_text":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 00:56 ET (04:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}